Patents by Inventor Wendy M. Blanda

Wendy M. Blanda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210236590
    Abstract: Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel.
    Type: Application
    Filed: October 5, 2020
    Publication date: August 5, 2021
    Inventors: Wendy M. Blanda, Mayssa Attar
  • Publication number: 20210121397
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Application
    Filed: January 5, 2021
    Publication date: April 29, 2021
    Inventors: Jeffrey L. EDELMAN, Patrick M. HUGHES, Thomas C. MALONE, Gerald W. DEVRIES, Joan-En CHANG-LIN, Jane-Guo SHIAH, Thierry NIVAGGIOLI, Lon T. SPADA, Wendy M. BLANDA
  • Publication number: 20210113592
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Application
    Filed: June 29, 2020
    Publication date: April 22, 2021
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Patent number: 10881608
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: January 5, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Patent number: 10869955
    Abstract: The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 22, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Guang-Liang Jiang, Catherine C. Turkel, Michael E. Stern, Christopher S. Schaumberg, Wendy M. Blanda
  • Patent number: 10792345
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 6, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Patent number: 10702539
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: July 7, 2020
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Publication number: 20190336441
    Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
    Type: Application
    Filed: July 19, 2019
    Publication date: November 7, 2019
    Inventors: Scott M. Whitcup, Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, James A. Burke
  • Patent number: 10363214
    Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: July 30, 2019
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, James A. Burke
  • Publication number: 20190038551
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.
    Type: Application
    Filed: September 10, 2018
    Publication date: February 7, 2019
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Publication number: 20190015425
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Application
    Filed: September 17, 2018
    Publication date: January 17, 2019
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Patent number: 10076526
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: September 18, 2018
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Patent number: 10076492
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 18, 2018
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Publication number: 20180207230
    Abstract: Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.
    Type: Application
    Filed: March 19, 2018
    Publication date: July 26, 2018
    Inventors: Wendy M. Blanda, Hongwen Ma Rivers, David A. Marsh, Michelle Luu
  • Patent number: 9919028
    Abstract: Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: March 20, 2018
    Assignee: Allergan, Inc.
    Inventors: Wendy M. Blanda, Hongwen Ma Rivers, David A. Marsh, Michelle Luu
  • Publication number: 20170368236
    Abstract: The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.
    Type: Application
    Filed: January 28, 2016
    Publication date: December 28, 2017
    Inventors: Guang-Liang Jiang, Catherine C. Turkel, Michael E. Stern, Christopher S. Schaumberg, Wendy M. Blanda
  • Publication number: 20170216414
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Patent number: 9622957
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: April 18, 2017
    Assignee: Allergan, Inc.
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Publication number: 20160271207
    Abstract: Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.
    Type: Application
    Filed: June 2, 2016
    Publication date: September 22, 2016
    Inventors: Wendy M. Blanda, Hongwen Ma Rivers, David A. Marsh, Michelle Luu
  • Publication number: 20160243032
    Abstract: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.
    Type: Application
    Filed: May 2, 2016
    Publication date: August 25, 2016
    Inventors: Glenn T. Huang, Thierry Nivaggioli, Lon T. Spada, Hiroshi Sugimoto, Wendy M. Blanda, James N. Chang, Orest Olejnik